

REUSABLE PEN · PLASTIC OR ANODIZED
ALUMINUM

DS02

One pen, thousands of doses. Rotate the dose ring, press to inject, and reuse for up to 3 years or 3,000 cycles. Durable plastic or anodized-aluminum housing. White-label ready, ISO 11608-2 compliant.

**3,000** cycles

Reusable lifespan

3 years

Service life

0.08–0.8 mL

Dose range

0.01 mL

Min step

3.0 mL

Cartridge

ISO 11608-2

Tested to

Specifications

Injection method	Manual — external rotation to set the dose, then press the actuator button
Dose-setting method	Twist adjustment; dose scale, rotation prompt sound, dose-progress window
Dose specifications	Six maximum doses: 0.08, 0.3, 0.5, 0.6, 0.75, and 0.8 mL
Minimum increment	0.01 mL per click
Built-in container	3.0 mL cartridge, ISO 11608-2 compliant
Usage type	Reusable, with a lifespan of 3 years or 3,000 cycles
Cartridge replacement	Threaded-connection refill holder
Shell material	Durable plastic or anodized-aluminum metal
Compatible needle	Pen needle, ISO 11608-2 compliant
Route of administration	Subcutaneous
Last-dose locking	Yes — confirms the full volume has been delivered
Regulatory status	CE-marking support; aligned with the European Medical Device Regulation

DIMENSIONS



WHY CUSTOMERS CHOOSE IT

**Reusable by design**

One pen serves for up to 3 years or 3,000 cycles, cutting cost-per-dose.

**Stable, accurate delivery**

A plunger with last-dose locking and clear audible and tactile feedback.

**Two housing options**

Durable plastic or anodized-aluminum metal to match your positioning.

**Wide cartridge compatibility**

Insulin, GLP-1, growth hormone, FSH, enoxaparin, thyroxine, peptides.

THE DEVICE

● Capped profile



● Anodized range



● Three components



● Color range



Waytop is a wholesale supplier of injection pens and related components. Regulatory market entry, local certifications and compliance are the buyer's responsibility. Waytop does not sell into markets where a given model is subject to an existing authorized distributor or patent. Intended applications, dose ranges and all clinical statements are determined by the final registered labeling for each market.